BACKGROUND: Pulmonary vein (PV) isolation with cryoballoon is a recently developed technique for the treatment of atrial fibrillation (AF) with acceptable mid-term results in terms of the success and safety. The purpose of our study is to identify the periprocedural complications, mid-term success rates and predictors of recurrence after AF ablation with cryoballoon. METHOD: A total of 236 patients (54% male, mean age 54.6 ± 10.45 years and 79.6% paroxysmal AF) with symptomatic AF underwent PV isolation with cryoballoon due to failure with ≥1 antiarrhythmic drug previously. Procedural success, complications and follow-up data were defined according to recent guidelines. RESULTS: Acute procedural success rate was 99.5%. Mean procedural and fluoroscopy times were 72.5 ± 5.3 and 14 ± 3.5 min. At a median of 18 (6-27) months follow-up, 80.8% of paroxysmal AF patients and 50.0% of persistent AF patients were free from AF recurrence. In multivariate regression analysis, body mass index (BMI) (hazard ratio (HR), 1.35; 95% confidence interval (CI), 1.18-2.93, p = 0.001), smoking (HR, 2.12; 95% CI, 1.36-6.67, p < 0.001), non-paroxysmal AF (HR, 1.26; 95% CI, 1.12-2.56, p = 0.024), duration of AF (HR, 1.42; 95% CI, 1.18-2.61, p = 0.015), left atrium (LA) diameter (HR, 2.42; 95% CI, 1.64-5.88, p < 0.001) and early AF recurrence (HR, 4.88; 95% CI, 2.86-35.6, p < 0.001) were independent predictors of AF recurrence following cryoablation. CONCLUSION: Our results showed that AF ablation with cryoballoon is effective and safe. Non-paroxysmal AF, duration of AF, smoking, BMI, LA diameter and early recurrence were found to be the most powerful predictors and could be helpful to select patients for appropriate therapeutic strategy.
BACKGROUND: Pulmonary vein (PV) isolation with cryoballoon is a recently developed technique for the treatment of atrial fibrillation (AF) with acceptable mid-term results in terms of the success and safety. The purpose of our study is to identify the periprocedural complications, mid-term success rates and predictors of recurrence after AF ablation with cryoballoon. METHOD: A total of 236 patients (54% male, mean age 54.6 ± 10.45 years and 79.6% paroxysmal AF) with symptomatic AF underwent PV isolation with cryoballoon due to failure with ≥1 antiarrhythmic drug previously. Procedural success, complications and follow-up data were defined according to recent guidelines. RESULTS: Acute procedural success rate was 99.5%. Mean procedural and fluoroscopy times were 72.5 ± 5.3 and 14 ± 3.5 min. At a median of 18 (6-27) months follow-up, 80.8% of paroxysmal AFpatients and 50.0% of persistent AFpatients were free from AF recurrence. In multivariate regression analysis, body mass index (BMI) (hazard ratio (HR), 1.35; 95% confidence interval (CI), 1.18-2.93, p = 0.001), smoking (HR, 2.12; 95% CI, 1.36-6.67, p < 0.001), non-paroxysmal AF (HR, 1.26; 95% CI, 1.12-2.56, p = 0.024), duration of AF (HR, 1.42; 95% CI, 1.18-2.61, p = 0.015), left atrium (LA) diameter (HR, 2.42; 95% CI, 1.64-5.88, p < 0.001) and early AF recurrence (HR, 4.88; 95% CI, 2.86-35.6, p < 0.001) were independent predictors of AF recurrence following cryoablation. CONCLUSION: Our results showed that AF ablation with cryoballoon is effective and safe. Non-paroxysmal AF, duration of AF, smoking, BMI, LA diameter and early recurrence were found to be the most powerful predictors and could be helpful to select patients for appropriate therapeutic strategy.
Authors: Anton A W Mulder; Maurits C E F Wijffels; Eric F D Wever; Johannes C Kelder; Lucas V A Boersma Journal: Pacing Clin Electrophysiol Date: 2011-09-02 Impact factor: 1.976
Authors: A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof Journal: Europace Date: 2012-08-24 Impact factor: 5.214
Authors: F D'Ascenzo; A Corleto; G Biondi-Zoccai; M Anselmino; F Ferraris; L di Biase; A Natale; R J Hunter; R J Schilling; S Miyazaki; H Tada; K Aonuma; L Yenn-Jiang; H Tao; C Ma; D Packer; S Hammill; F Gaita Journal: Int J Cardiol Date: 2012-05-22 Impact factor: 4.164
Authors: Gaetano Senatore; Giuseppe Stabile; Emanuele Bertaglia; Giovanni Donnici; Antonio De Simone; Franco Zoppo; Pietro Turco; Pietro Pascotto; Massimo Fazzari Journal: J Am Coll Cardiol Date: 2005-03-15 Impact factor: 24.094
Authors: Douglas L Packer; Robert C Kowal; Kevin R Wheelan; James M Irwin; Jean Champagne; Peter G Guerra; Marc Dubuc; Vivek Reddy; Linda Nelson; Richard G Holcomb; John W Lehmann; Jeremy N Ruskin Journal: J Am Coll Cardiol Date: 2013-03-21 Impact factor: 24.094
Authors: David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry Journal: JAMA Date: 2010-01-27 Impact factor: 56.272
Authors: Kivanc Yalin; Amr Abdin; Evgeny Lyan; Noureddin Sawan; Spyridon Liosis; Christian Elsner; Alexander Jobs; Ben Brüggemann; Jelena Koester; Ingo Eitel; Charlotte Eitel; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2018-02-28 Impact factor: 5.460
Authors: Shaojie Chen; Boris Schmidt; Stefano Bordignon; Fabrizio Bologna; Takahiko Nagase; Laura Perrotta; K R Julian Chun Journal: Arrhythm Electrophysiol Rev Date: 2018-03
Authors: Jesus M Paylos; Luis Azcona; Lourdes Lacal; Marisol Paradela; Carmen Cilleros; Ildefonso Del-Campo; Clara Ferrero Rn Carlos Martínez; Aracelis Morales Journal: J Atr Fibrillation Date: 2016-04-30